-- Total operating costs in 2007 increased 6% to $6.7 million from $6.3
million in the previous year.
-- Net loss attributable to common stockholders totaled $2.9 million, or
$0.24 per basic and diluted share, in 2007, a 6.8% decline from $3.2
million, or $0.27 per basic and diluted share, reported for 2006.
Joe W. Martin, Chief Executive Officer of Milestone, stated, "Looking ahead, our focus in 2008 will be largely centered on increasing sales of the STA System, both domestically and internationally, as well as supporting sales of our legacy CCLAD system, CompuDent, and driving recurring orders of the disposable hand pieces used in conjunction with both instruments. The challenge going forward will be leveraging creative and tactical advertising and proactive marketing strategies to spread the 'right' message about the STA System to each and every dentist."
Continuing, Martin added, "Worldwide, we estimate that over 35 million dental injections have been administered to patients with either the STA or CompuDent systems, to date. Moreover, our patented CompuFlo technology, embedded in the STA System, has been the subject of more than 50 publications validating the efficacy and safety of the technology in a wide range of medical injection applications. In 2008, we will accelerate our pursuit of collaborative opportunities with medical, pharmaceutical and healthcare companies interested in developing new product applications using CompuFlo, in order to build and grow long term shareholder value in Milestone."
"Although there is still a lot of work to do, I believe that Milestone
is well positioned to begin demonstrating much improved sales growth from
our existing product line as our new marketing messages take hold and our
market penetration efforts gain greater traction. Moreover, our
results-driven game plan for leveraging CompuFlo to introduce innovative
|SOURCE Milestone Scientific, Inc.|
Copyright©2008 PR Newswire.
All rights reserved